医薬品市場における世界の患者アクセス - 2030 年までの業界動向と予測

 医薬品市場分析と規模による患者アクセス

拒否管理の重要性の高まり、医療費削減の必要性の高まり、患者数の急増に伴う健康保険の需要の増加、償還ポリシーの率の低下は、2023年から2030年の予測期間中に医薬品による患者アクセス市場の成長を後押しする可能性のある要因の一部です。一方、新興ヘルスケア市場からのアプリケーションの増加は豊富な機会をもたらし、予測期間中に医薬品による患者アクセス市場の成長につながります。

Data Bridge Market Research の分析によると、2022 年に 102 億米ドルだった医薬品市場への患者アクセスは、2023 年から 2030 年の予測期間中に 6.75% の CAGR で成長し、2030 年には 172 億米ドルに達すると予想されています。市場価値、成長率、セグメンテーション、地理的範囲、主要プレーヤーなどの市場シナリオに関する洞察に加えて、Data Bridge Market Research がまとめた市場レポートには、詳細な専門家の分析、患者の疫学、パイプライン分析、価格分析、規制の枠組みも含まれています。

医薬品市場の範囲とセグメンテーションによる患者アクセス  

Market Definition

A pharmaceutical drug, also known as a medication or medicine, is a chemical substance used to treat, cure, prevent, diagnose, or promote health. Drugs were traditionally obtained through the extraction of medicinal plants, but more recently through organic synthesis.

Patient Access with Pharmaceutical Drugs Market Dynamics

Drivers

• Rise in chronic diseases

The number of people who have chronic diseases such as rheumatoid arthritis, hypertension, diabetes, and cancer has increased as a result of the ageing population. The growth of the market during this time was significantly impacted by the demand for pharmaceuticals used to treat these diseases, which was driven by the expansion of the patient pool. These are the certain reasons which propel the market growth.

• New Methods for Drug Discovery

During the forecast period, new technologies, including stem cell and organ chip technologies will propel the pharmaceutical medicines industry. Drug trials are being conducted differently as a result of stem cell and organ-on-chip technology. Micro-engineered biometric devices called "organ on chips" imitate organ systems' functions, mechanics, and physiological reactions. Organ on chip and stem cell technologies are used in drug trial processes such target discovery, validation, target based screening, and phenotypic screening. These technologies are significantly lowering the expenses associated with drug discovery and producing accurate predictions of therapeutic effectiveness and human safety. Therefore, it is anticipated that the pharmaceutical pharmaceuticals market will be driven by inexpensive drug discovery costs and precise findings produced by these technologies.

Opportunities

• Use of biomarker for drug development

Biomarkers are increasingly being used by pharmaceutical companies in the drug development process to shorten the time it takes to bring a product to market. Biomarkers objectively measure and evaluate biological indicators for biological processes, pathogenic processes, or pharmacological responses to a therapeutic intervention. They can predict drug efficacy faster than traditional clinical endpoints, which are the points at which an unwanted or abnormal effect of the drug is observed, indicating withdrawal from therapy. Companies like Genentech and Janssen are investing more in biomarkers to better understand the efficacy of a potential respiratory drug. Janssen, for example, collaborates with U-BIOPRED (unbiased biomarkers in the prediction of respiratory disease outcomes), a European group dedicated to learning more about severe respiratory disease.

Restraints/Challenges

• High costs of drugs

The high cost of drugs is a major issue for citizens in many countries. There is a lot of pressure to cut costs and show value. Political uncertainty and persistent economic stress in many countries are jeopardizing public health care funding. In less developed countries, a lack of cost-effective drugs has influenced population health and resulted in a low average life expectancy. As a result, pharmaceutical companies in countries such as Chad, Macedonia, and Serbia are under pressure to lower drug prices. The high costs of drugs are putting a strain on pharmaceutical drug manufacturers' revenues.

• Loss of confidentiality and security breaches

Loss of confidentiality and security breaches, as well as a shortage of skilled IT professionals, are likely to hamper the growth of the patient access to pharmaceutical drugs market during the forecast period. The rising cost of deployment and low patient adoption will be the biggest and most pressing challenge to market growth.

This patient access with pharmaceutical drugs market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the patient access with pharmaceutical drugs market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Global Patient Access with Pharmaceutical Drugs Market Scope

The patient access with pharmaceutical drugs market is segmented on the basis of dimensions, product and service, delivery mode, and end user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Dimensions

• Marketing Approvals
• Time of Marketing Approval
• Coverage
• Cost Sharing
• Conditions of Reimbursement
• Marketing Approval to Reimbursement
• Beneficiaries Control Choice
• Evenness of the Availability of Drugs

Product and Service

• Services
• Support and Maintenance Services
• Implementation Services
• Training and Education Services
• Software
• Eligibility Verification Software
•  Medical Necessity Management Software
•  Pre-certification and Authorization Software
•  Claims Denial and Appeal Management
•  Payment Estimation Software
•  Claims payment assessment and processing software
• Other software

 Delivery Mode

• Web and Cloud-Based Solutions
• On-Premises Solutions

 End User

• Healthcare Providers
• HCIT Outsourcing Companies
• Other End Users

Patient Access with Pharmaceutical Drugs Market Regional Analysis/Insights

The patient access with pharmaceutical drugs market is analyzed and market size insights and trends are provided by country, dimensions, product and service, delivery mode, and end user as referenced above.

The countries covered in the patient access with pharmaceutical drugs market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America dominates the patient access with pharmaceutical drugs market due to the growth in healthcare spending, the need to lower healthcare costs, and the proliferation of many healthcare companies.

Asia-Pacific is expected to grow at the highest growth rate in the forecast period of 2023 to 2030 owing to the growing demand for patient access solutions.

レポートの国別セクションでは、市場の現在および将来の傾向に影響を与える国内市場における個別の市場影響要因と規制の変更も提供しています。下流および上流のバリュー チェーン分析、技術動向、ポーターの 5 つの力の分析、ケース スタディなどのデータ ポイントは、個々の国の市場シナリオを予測するために使用される指標の一部です。また、国別データの予測分析を提供する際には、グローバル ブランドの存在と可用性、および地元および国内ブランドとの競争が激しいか少ないために直面​​する課題、国内関税と貿易ルートの影響も考慮されます。

ヘルスケアインフラの成長 導入基盤と新技術の浸透

医薬品による患者アクセス市場では、各国の医療費支出の資本設備増加、医薬品による患者アクセス市場向け各種製品のインストールベース、ライフライン曲線を使用した技術の影響、医療規制シナリオの変化とそれらが医薬品による患者アクセス市場に与える影響など、詳細な市場分析も提供しています。データは、2011年から2021年までの履歴期間について利用可能です。

医薬品市場シェア分析による競争環境と患者アクセス

医薬品による患者アクセス市場の競争状況は、競合他社ごとに詳細を提供します。含まれる詳細には、会社概要、会社の財務状況、収益、市場の可能性、研究開発への投資、新しい市場への取り組み、世界的なプレゼンス、生産拠点と施設、生産能力、会社の強みと弱み、製品の発売、製品の幅と広さ、アプリケーションの優位性などがあります。提供されている上記のデータ ポイントは、医薬品による患者アクセス市場に関連する会社の焦点にのみ関連しています。

医薬品の患者アクセス市場で活動している主要企業には以下のものがあります。

• マッケソンコーポレーション（米国）
• エピックシステムズコーポレーション（米国）
• サーナーコーポレーション（米国）
• コグニザント（米国）
• エクスペリアン インフォメーション ソリューションズ (米国)
• 3M（米国）
• コニファーヘルスソリューションズ LLC (米国)
• オプタム社（米国）
• アドバイザリーボードセンター（米国）
• クレーンウェアグループ（英国）
• Kareo, Inc (米国)
• SSIグループLLC（米国）
• アキュレグ（米国）
• ゼロックス社（米国）
• チェンジヘルスケア（米国）
• キュラス（米国）
• カーディナルヘルス（米国）

SKU-56962